Form 4: Verrica Pharmaceuticals Interim CFO Acquires Restricted Stock Units

Sentiment:

SEC Form 4 Filing


Interim CFO John J. Kirby of Verrica Pharmaceuticals acquired 54,267 restricted stock units (RSUs) on November 6, 2024, which will vest on May 4, 2025, subject to continued service.

Summary

  • On November 6, 2024, John J. Kirby, Interim CFO of Verrica Pharmaceuticals, acquired 54,267 shares of common stock in the form of restricted stock units (RSUs).
  • The RSUs were granted as an award and did not involve a purchase price.
  • These RSUs will vest in full on May 4, 2025, contingent upon Kirby's continuous service with the company through that date.
  • Following the transaction, Kirby beneficially owns 54,267 shares of Verrica Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of RSUs is a standard practice and indicates confidence in the executive's continued service and the company's future prospects.

Positives

  • The grant of RSUs to the Interim CFO aligns his interests with the long-term success of the company.
  • The vesting schedule encourages continued service and commitment from the Interim CFO.

Future Outlook

The vesting of the RSUs on May 4, 2025, is contingent upon the Interim CFO's continued service with the company.

Industry Context

Grants of restricted stock units are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value and incentivizing long-term performance.

Comparison to Industry Standards

  • Executive compensation packages, including RSU grants, are common in the pharmaceutical industry to attract and retain talent.
  • Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize RSUs as part of their executive compensation plans.
  • The size and vesting schedule of RSU grants vary depending on the company's size, performance, and the executive's role.

Stakeholder Impact

  • Shareholders may view the RSU grant positively as it aligns management's interests with the company's long-term success.
  • Employees may see the RSU grant as a sign of the company's commitment to its leadership.

Key Dates

DateDescription
11/06/2024Date of transaction: Interim CFO John J. Kirby acquired 54,267 restricted stock units.
05/04/2025Vesting date: The 54,267 RSUs will vest in full, subject to continuous service.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.